Health

Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism

Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...

2023-01-06 18:00 1615

SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock

- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South Korea, Jan. 5, 2023 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, today announced that Mr.Donghoon Lee, the Chief Executive Officer and President of SK Biophar...

2023-01-06 09:10 1547

WAYCEN, the first medical AI company to win 4 CES 2023 innovation awards "Proved K-Medtech"

* Company specialized in AI Medtech, WAYCEN, won CES innovation awards for two years in a row * WAYCEN swept CES 2023 innovation awards with medical AI products, collaborated with the medical staff SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- The company specialized in AI Medtech, WAYCEN ...

2023-01-06 00:00 1766

Global Times: China shifts COVID policy with necessary conditions

BEIJING, Jan. 5, 2023 /PRNewswire/ -- After three years' hard efforts to keep COVID-19 at bay,China has optimized its virus response and come up with a major shift in its epidemic policy by downgrading COVID management and announcing the reopening of international borders fromJanuary 8, 2023. Glo...

2023-01-05 23:21 1947

Standigm cited as 'Top 10 Generative AI-based startup based on VC Investment, 2019-2021' in Gartner® report

SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it had been cited in the 2022 Gartner Emerging Tech: Venture Capital Growth Insights for Gen...

2023-01-05 22:00 1763

Yunji Successfully Concludes its New Year Festive Goods Shopping Festival

HANGZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that the final large-scale promotional event before the Lunar New Year, the New Year Festive Goods Shopping Festival ("the Event...

2023-01-05 19:00 3272

So-Young Regains Compliance with Nasdaq Minimum Bid Price Requirement

BEIJING, Jan. 5, 2023 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that it has received a written...

2023-01-05 18:30 2982

B dot Medical to Install Its First Practical Ultra-compact Proton Therapy System at Hospital in Tokyo

- Memorandum of Understanding Signed with Edogawa Hospital - TOKYO, Jan. 5, 2023 /PRNewswire/ -- B dot Medical Inc. has signed a memorandum of understanding with Edogawa Hospital inJapan for the installation of the company's first practical ultra-compact proton therapy system, which means the fi...

2023-01-05 15:00 1706

Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Chairman and CEO, Dr.Dajun Yang, has accep...

2023-01-05 09:00 2379

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program * Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties * Collaboration based on synergies between Adcendo ...

2023-01-05 09:00 1294

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...

2023-01-05 00:00 2767

Lunit to Supply AI Solution for Chest X-Ray Analysis to Albert Einstein, Latin America's Largest Hospital

* Lunit signed a software license agreement with the Hospital Israelita Albert Einstein,Latin America's top medical institution, to provide its AI-based chest x-ray solution * Under the agreement, Lunit will supply its AI solution for chest x-ray image analysis to the Hospital Israelita Alber...

2023-01-04 21:20 2449

Waterdrop and Jemincare Collaborate on the "Digital Service Platform for CKD Patients"

BEIJING, Jan. 4, 2023 /PRNewswire/ -- Waterdrop and Jemincare recently reached a cooperation, according to which both sides will jointly launch the "Digital Service Platform for CKD Patients". Featuring both online and offline service modules ranging from follow-up visits and consultation with do...

2023-01-04 21:00 3017

OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneurRobert Forrester and venture capitalist Chau Khuong as independent ...

2023-01-04 21:00 1970

Sihuan Pharmaceutical(0460.HK): Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing

Accelerating the Layout of Diabetes and Complications HONG KONG, Jan. 4, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; stock code: 0460) is pleased to announc...

2023-01-04 15:52 3305

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., ...

2023-01-03 23:25 1631

Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test

IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthro...

2023-01-03 22:24 1007

Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023

SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023. Pavel Printsev,...

2023-01-03 22:00 1227

ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC

* PRO1184 first-in human study initiated and first patients dosed * PRO1160 first-in-human study cleared for initiation in the US * Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform SUZHOU, China and WOODINVILLE, Wash., Jan. ...

2023-01-03 20:00 2497

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2023-01-03 14:10 1908
1 ... 119120121122123124125 ... 280